shell3
2 months ago
Algernon Announces Increase to Private Placement
Received a email just now but not posted yet OTC but here’s a quote and my math comes to 3,400,000 shares with Warrants the same plus Brokers fee paid in shares
announces an increase to its non-brokered private placement, previously announced on July 11, 2024, from gross proceeds of $250,000 to $408,000 (the “Offering”) of units (the “Units”) at an issue price of $0.12 per Unit. Each Unit will consist of one Class A common share in the capital of the Company (a “Common Share”) and one Common Share purchase warrant (a “Warrant”). Each Warrant will entitle the holder to acquire one Common Share (a “Warrant Share”) at an exercise price of $0.24 per Warrant Share for a period of 2 years from the date of issuance (the “Expiry Date”), subject to acceleration of the Expiry Date as described below. The Offering is expected to close on August 1, 2024
That’s $0.12 is $AGN price or $0.087 $AGNPF for the Unit and Warrants are just doubled the price
P.S. ••• It just posted OTC
https://www.otcmarkets.com/stock/AGNPF/news/story?e&id=2933271
tcm55
6 months ago
Neuroplasticity, dendritic spines, 1hr 40mins. He sites many papers, mostly in mouse/rat trials, in this presentation where neuroplasticity is observed, but it seems that the AGN 'microdosing for Stroke' concept is unique.
Yes, the when and where type of data for the clinical trials could be announced soon. Maybe Oregon where it's legal for research?
I've held this long already and will hold through the finish...
...GLTA...
tcm55
6 months ago
Sure great to see this all finally progressing.
“Investigating neuroplasticity in a clinical setting, as a potential new treatment approach for ischemic stroke patients, is a new and promising area of research,” said Christopher J. Moreau CEO of Algernon. “Algernon is a global leader in this important area of research, and we look forward to further advancing the stroke program through our planned Phase 2a DMT Stroke study.”
Phase 2a Stroke Study Design
Subjects with a confirmed diagnosis of ischemic stroke will be randomized in blinded fashion to receive either DMT or placebo. The primary outcome measure of the study will be safety, and information will be gained on measures of efficacy including preservation of brain tissue, motor recovery, depression and numerous biomarkers linked to the pathophysiology of stroke.
The veteran community has discussed TBI and PTSD issues and treatments involving Psycs. This group may also be a area of recruitment for future stroke/TBI research. There are already a few PTSD studies...
...GLTA...
McMagyar
6 months ago
Algernon going to move forward with 40 patient phase 2 for isechemic stroke.
Is there a Stroke Victim advocacy group which could help cover costs?
Can’t wait for results! 6 days of treatment..
40 patients.. normally a clinical trial takes forever..
How common is an ischemic stroke?
Strokes are very common. Worldwide, strokes rank second among the top causes of death. In the United States, they rank fifth. Strokes are also one of the leading causes of disability worldwide. Ischemic strokes make up about 85% of all strokes.
No shortage of need..
Stroke statistics
In 2021, 1 in 6 deaths from cardiovascular disease was due to stroke.1
Every 40 seconds, someone in the United States has a stroke.2 Every 3 minutes and 14 seconds, someone dies of stroke.1
Every year, more than 795,000 people in the United States have a stroke. About 610,000 of these are first or new strokes.2
About 185,000 strokes—nearly 1 in 4—are in people who have had a previous stroke.2
About 87% of all strokes are ischemic strokes, in which blood flow to the brain is blocked.2
Stroke-related costs in the United States came to nearly $56.5 billion between 2018 and 2019.2 This total includes the cost of health care services, medicines to treat stroke, and missed days of work.
Stroke is a leading cause of serious long-term disability.2 Stroke reduces mobility in more than half of stroke survivors age 65 and older.2
I think the goal will be to administer the first sub psych dose of DMT immediately after diagnosis..
A positive phase 2a.. would be a very large step for algernon
“Investigating neuroplasticity in a clinical setting, as a potential new treatment approach for ischemic stroke patients, is a new and promising area of research,